GIFLF:OTCMKTS
Grifols SA Class A
US$Â 11.13
0.00%
(0.00) Siku 1
15 Sep, 15:11:14 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya GIFLF...
Mtaji wa soko
6.68B
Wastani wa kiasi cha mauzo
543.00
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
US$Â 12.90
Chini kwa wiki 52
US$Â 10.13
Beta
0.90
Hisa za wawekezaji
426.13M
Idadi ya wafanyakazi
elfu 25
Mtaji wa soko
6.68B
Wastani wa kiasi cha mauzo
543.00
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
US$Â 12.90
Chini kwa wiki 52
US$Â 10.13
Beta
0.90
Hisa za wawekezaji
426.13M
Idadi ya wafanyakazi
elfu 25
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
ad-hoc-news.de
·
saa 5 zilizopita
Grifols stock trades at EUR 10.03 with EUR 6.8 billion market value
AD HOC NEWS
·
siku 2 zilizopita
Grifols stock ends the week at EUR 9.88 within a EUR 9.73-9.97 range
AD HOC NEWS
·
siku 3 zilizopita
Grifols stock after-hours at EUR 9.88: plus 0.51 percent
AD HOC NEWS
·
siku 3 zilizopita
Grifols signed a 40 GWh PPA and Grifols stock gained 1.22 percent
Wasifu
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
Kuhusu Grifols SA Class A
Afisa Mkuu Mtendaji (CEO)Nacho Abia
Wafanyakazielfu 25
Lilianzishwa18 Nov 1940
Makao makuu-
Sekta-
Tovutigrifols.com